Amphastar Pharmaceuticals Inc ((AMPH)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amphastar Pharmaceuticals’ recent earnings call revealed a resilient performance, marked by robust sales growth in key products and strategic pipeline expansions. Despite facing challenges such as declines in specific product sales and increased competition, the company demonstrated a strong financial standing. Notably, the litigation provision and reduced net income were highlighted as significant hurdles.
Strong Quarterly Performance
Amphastar Pharmaceuticals reported impressive financial results for the third quarter of 2025, achieving net revenues of $191.8 million. The company recorded a GAAP net income of $17.4 million, or $0.37 per diluted share. On a non-GAAP basis, adjusted net income stood at $44.7 million, or $0.93 per diluted share, underscoring the company’s robust financial health.
BAQSIMI and Primatene MIST Growth
The earnings call highlighted significant growth in BAQSIMI and Primatene MIST sales. BAQSIMI generated $53.6 million in total sales, marking a 14% increase year-over-year, while Primatene MIST sales rose by 11% year-over-year. This growth indicates strong consumer engagement in the over-the-counter respiratory space.
Pipeline Expansion
Amphastar expanded its pipeline through an exclusive in-licensing agreement, securing U.S. and Canadian rights to three novel peptide candidates targeting oncology and ophthalmology markets. This strategic move is expected to bolster the company’s future growth prospects.
Regulatory Progress
The company achieved FDA approval for its iron sucrose injection, AMP-002, which generated $2.4 million in sales this quarter. This regulatory milestone reflects Amphastar’s commitment to expanding its product offerings.
Manufacturing Expansion
Amphastar is set to enhance its operational capabilities by quadrupling production capacity at its Rancho Cucamonga headquarters. This expansion is expected to strengthen the company’s operational agility.
Decline in Glucagon Injection Sales
The earnings call noted a 49% decline in glucagon injection sales, which fell to $13.6 million due to decreased volumes and heightened competition.
Epinephrine Sales Drop
Epinephrine sales experienced a 12% decrease, dropping to $18.8 million, primarily attributed to increased competition in the market.
Litigation Impact
General and administrative spending saw a significant increase due to a litigation provision related to a recent civil case verdict, impacting the company’s financials.
Gross Margin Decline
Amphastar’s gross margins declined to 51.4% from 53.3%, driven by pricing declines and competitive pressures, highlighting a challenge in maintaining profitability.
Net Income Decrease
Net income for the quarter decreased to $17.4 million, or $0.37 per share, compared to $40.4 million, or $0.78 per share, in the previous year, reflecting the financial challenges faced by the company.
Forward-Looking Guidance
Amphastar Pharmaceuticals provided an optimistic outlook for future growth, driven by strategic innovation and manufacturing expansion. The company plans to launch new products, including AMP-007 and AMP-015 in 2026, and AMP-018 and AMP-004 in 2027. With a potential market opportunity exceeding $60 billion, the company is poised for a robust growth trajectory.
In summary, Amphastar Pharmaceuticals’ earnings call showcased a resilient performance amidst challenges. The company achieved strong sales growth in key products and expanded its pipeline strategically. Despite facing declines in some product sales and increased competition, Amphastar’s forward-looking guidance indicates a promising future driven by innovation and expansion.